Century Therapeutics Inc (IPSC) Institutional Ownership & 13F Filings (Q2 2026)

IPSC ranks #4596 out of 37503 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

IPSC is a top-conviction position for Versant Venture Management, LLC — at 18.3% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in IPSC belongs to Ra Capital Management, L.p., but the position matters far more to Versant Venture Management, LLC, who has 18.3% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

BlackRock has added to its IPSC position for two straight quarters, increasing it by $19.2M to reach $19.8M today.

Prudential Financial Inc has trimmed its IPSC position for two straight quarters, cutting it by $13.9K while still holding $45.6K.

IPSC is down 1.4% today, but institutions show net buying of $56.9M this quarter — a divergence between today's price move and the underlying institutional flow.

IPSC reported a net loss of $109.8M over the trailing twelve months.

• Not yet profitable — net loss of $109.8M over the trailing twelve months
• Revenue grew 1556.5% year over year
• Net income declined year over year, from -$23.3M to -$109.8M
• Operating cash flow was negative, using $103.9M in cash
• Current ratio of 5.97x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.41x equity — within a conventional range